Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Analysts at Craig Hallum

Equities research analysts at Craig Hallum began coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research report issued to clients and investors on Friday, MarketBeat.com reports. The firm set a “buy” rating and a $12.00 price target on the stock. Craig Hallum’s price objective suggests a potential upside of 228.77% from the stock’s current price.

Several other research analysts have also commented on EPRX. RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company.

Eupraxia Pharmaceuticals Stock Up 2.8 %

NASDAQ:EPRX opened at $3.65 on Friday. Eupraxia Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $5.15. The firm has a market capitalization of $130.12 million and a P/E ratio of -5.07. The company has a fifty day moving average of $3.13 and a 200 day moving average of $2.91.

Institutional Trading of Eupraxia Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC purchased a new stake in shares of Eupraxia Pharmaceuticals in the 4th quarter worth about $31,000. Raymond James Financial Inc. purchased a new stake in shares of Eupraxia Pharmaceuticals in the 4th quarter worth about $37,000. Finally, Bank of Montreal Can grew its position in shares of Eupraxia Pharmaceuticals by 15.2% in the 4th quarter. Bank of Montreal Can now owns 56,750 shares of the company’s stock worth $178,000 after buying an additional 7,500 shares during the period.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.